logo-loader
RNS
Redx Pharma PLC

Redx Pharma plc - Results of Open Offer and General Meeting

RNS Number : 3958J
Redx Pharma plc
21 December 2020
 

THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

THE INFORMATION COMMUNICATED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

Redx Pharma plc

("Redx" or "the Company")

 

Results of Open Offer and General Meeting 

 

Alderley Park, 21 December 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis announces the results of its Open Offer and General Meeting.

 

On 2 December 2020, Redx announced that it had conditionally raised £25.5 million by means of a Placing of 45,603,575 new Ordinary Shares (the "Placing Shares") at 56 pence per share (the "Issue Price"). In addition, all Qualifying Shareholders were provided with an opportunity to subscribe for an aggregate of up to 3,904,948 Open Offer Shares on the basis of 1 Open Offer Share for every 50 existing Ordinary Shares held on the Record Date, at the Issue Price.

 

The Company has conditionally raised £128,837 through the Open Offer, having received valid acceptances in respect of 230,066 Open Offer Shares from Qualifying Shareholders, representing approximately 5.89 per cent. of the Open Offer Shares offered. All eligible applications received from Qualifying Shareholders will be satisfied in full.

 

Directors participation was as follows:

 

 

 

Director

 

Placing shares subscribed for

 

Open offer shares subscribed for

 

Post subscription holding

% of post transaction share capital

Iain Ross

-

35,130

251,000

0.09

Peter Presland

-

27,376

146,225

0.05

Sarah Gordon Wild

892,858

-

892,858

0.33

Lisa Anson

89,286

-

89,286

0.03

 

The Placing and Open Offer was conditional, amongst other things, upon the passing of certain Resolutions at the General Meeting, held today at 11am. All the Resolutions proposed at the General Meeting were duly passed by the requisite majority.

 

The Placing Shares, the new Ordinary Shares to be issued pursuant to the Open Offer and the Conversion Shares are expected to be admitted to trading on AIM on 22 December 2020.

 

Capitalised terms used in this announcement shall, unless defined otherwise, have the same meaning as in the announcement of the Placing and Open Offer made by the Company on 2 December 2020.

 

 

For further information, please contact:




Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Chairman

Lisa Anson, Chief Executive




SPARK Advisory Partners (Nominated Adviser)

 T: +44 203 368 3550

Matt Davis/Adam Dawes




WG Partners LLP (Broker)

T: +44 20 3705 9330

Claes Spång/Chris Lee/David Wilson






FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin


 

 


 

About Redx Pharma Plc

 

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

 

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMBDBDDSDDDGGB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read